2023-08-07 16:55:51 ET
- CRISPR Therapeutics press release ( NASDAQ: CRSP ): Q2 GAAP EPS of -$0.98 beats by $1.12 .
- Revenue of $70M.
- Total collaboration revenue was $70.0 million for the quarter ended June 30, 2023. Collaboration revenue for the second quarter of 2022 was not material. Collaboration revenue recognized in the second quarter of 2023 was primarily attributable to a research milestone achieved during the current quarter in connection with a non-exclusive license agreement with Vertex.
- As part of the licensing agreement, a research milestone was achieved in the second quarter of 2023, triggering a payment of $70 million to be received by CRISPR Therapeutics in the third quarter of 2023.
For further details see:
CRISPR Therapeutics GAAP EPS of -$0.98 beats by $1.12, revenue of $70M